Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Peripheral neuropathy is a major dose-limiting side effect of many chemotherapeutic agents. The type and degree of neuropathy depend on the chemotherapy drug, dose-intensity, and cumulative dose. Disabling peripheral neuropathy has a significant negative impact on quality of life. Accordingly, a reliable assessment of chemotherapy-induced peripheral neurotoxicity is necessary, especially if potential neuroprotective agents are to be investigated. Chemoprotectants are agents that have been developed to ameliorate the toxicity associated with cytotoxic drugs. They aim to provide site-specific protection for normal tissues, without compromising antitumor efficacy. Several chemoprotectant compounds have been studied in recent clinical trials. These trials must include sufficient dose-limiting events for study and assessment of both toxicity and antitumor effect. A future avenue of investigation includes the identification of patients at higher risk for the development of peripheral neuropathy based on their genotype. Identification of these higher-risk patients may enable us to devise prevention strategies prior to the onset of this potentially debilitating complication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ajani JA, Welch SR, Raber MNet al (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:47–59

    Google Scholar 

  2. Apfel SC (2000) Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. Cancer Invest 18:564–573

    CAS  PubMed  Google Scholar 

  3. Barohn RJ (1998) Approach to peripheral neuropathy and neuronopathy. Semin Neurol 18:7–18

    CAS  PubMed  Google Scholar 

  4. Capizzi RL (1999) The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26:3–21

    CAS  Google Scholar 

  5. Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20:3478–3483

    Article  CAS  PubMed  Google Scholar 

  6. Cascinu S, Cordella L, Del Ferro E et al (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 13:26–32

    CAS  PubMed  Google Scholar 

  7. Casey EB, Fullerton PM, Jelliffe AW (1970) Vincristine neurotoxicity: a clinical and electrophysiological study of eighteen patients. Clin Sci 38:23P–24P

    CAS  Google Scholar 

  8. Casey EB, Jellife AM, Le Quesne PM, Millett YL (1973) Vincristine neuropathy. Clinical and electrophysiological observations. Brain 96:69–86

    CAS  PubMed  Google Scholar 

  9. Chaudhry V, Chaudhry M, Crawford TO et al (2003) Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60:337–340

    CAS  PubMed  Google Scholar 

  10. Chaudhry V, Rowinsky EK, Sartorius SE et al (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35:304–311

    CAS  PubMed  Google Scholar 

  11. Chaudhry V, Cornblath DR, Corse A et al (2002) Thalidomide-induced neuropathy. Neurology 59:1872–1875

    CAS  PubMed  Google Scholar 

  12. Colombo N, Bini S, Miceli D et al (1995) Weekly cisplatin ± glutathione in relapsed ovarian carcinoma. Int J Gynecol Cancer 5:81–86

    Article  PubMed  Google Scholar 

  13. De Vos F (2003) A randomized phase II study of paclitaxel (P) with carboplatin (C) ± amifostine (A) as first line treatment in advanced ovarian carcinoma. Proc Amer Soc Clin Oncol 22:448

    Google Scholar 

  14. Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303

    CAS  PubMed  Google Scholar 

  15. Extra JM, Marty M, Brienza S, Misset JL (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13–22

    CAS  Google Scholar 

  16. Fischer SJ, Podratz JL, Windebank AJ (2001) Nerve growth factor rescue of cisplatin neurotoxicity is mediated through the high affinity receptor: studies in PC12 cells and p75 null mouse dorsal root ganglia. Neurosci Lett 308:1–4

    Article  CAS  PubMed  Google Scholar 

  17. Gelmon K, Eisenhauer E, Bryce C et al (1999) Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17:3038–3047

    CAS  PubMed  Google Scholar 

  18. Gibbels E, Scheid W, Wieck HH, Kinzel W (1973) [Thalidomide neuropathy in the late stage. A clinical documentation]. Fortschr Neurol Psychiatr Grenzgeb 41:378–417

    CAS  PubMed  Google Scholar 

  19. Hafstrom T (1967) Polyneuropathy after neurosedyn (thalidomide) and its prognosis. Acta Neurol Scand 43 [Suppl32]:1–41

    Google Scholar 

  20. Hildebrandt G, Holler E, Woenkhaus M et al (2000) Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy. Ann Oncol 11:743–747

    Article  CAS  PubMed  Google Scholar 

  21. Hilpert F (2003) Neuroprotection with amifostine in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy-a double-blind, placebo-controlled, randomized phase II-study of the AGO Ovarian Cancer Study Group. Proc Amer Soc Clin Oncol 22:448

    Google Scholar 

  22. Hovestadt A, van der Burg ME, Verbiest HB et al (1992) The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol 239:143–146

    CAS  PubMed  Google Scholar 

  23. Igarashi M, Thompson EI, Rivera GK (1995) Vincristine neuropathy in type I and type II Charcot-Marie-Tooth disease (hereditary motor sensory neuropathy). Med Pediatr Oncol 25:113–116

    CAS  PubMed  Google Scholar 

  24. Jacobson S, Loprinzi C (2002) Glutamine for preventing paclitaxel-associated malgias and arthralgias: unfortunately a “no go.” Proc Amer Soc Clin Oncol 1460

  25. Kemp G, Rose P, Lurain J et al (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101–2112

    CAS  PubMed  Google Scholar 

  26. Klimberg VS, McClellan JL (1996) Claude H. Organ, Jr. Honorary Lectureship. Glutamine, cancer, and its therapy. Am J Surg 172:418–424

    Article  CAS  PubMed  Google Scholar 

  27. Lee RT, Oster MW, Balmaceda C et al (1999) Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel. Ann Oncol 10:1245–1247

    Article  CAS  PubMed  Google Scholar 

  28. Links M, Lewis C (1999) Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 57:293–308

    Article  CAS  PubMed  Google Scholar 

  29. Ma W, Eisenach JC (2002) Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 6:1037–1047

    Article  Google Scholar 

  30. Maestri A (2002) Acetyl-L-carnitine (ALCAR) in patients with chemotherapy-induced peripheral sensory neuropathy. Proc Amer Soc Clin Oncol 2807

  31. McDonald ES, Windebank AJ (2002) Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis 9:220–233

    Article  CAS  PubMed  Google Scholar 

  32. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer, 47:207–214

    Google Scholar 

  33. Nakamura Y, Shimizu H, Nishijima C et al (2001) Delayed functional recovery by vincristine after sciatic nerve crush injury: a mouse model of vincristine neurotoxicity. Neurosci Lett 304:5–8

    Article  CAS  PubMed  Google Scholar 

  34. Nozaki-Taguchi N, Chaplan SR, Higuera ES, et al (2001) Vincristine-induced allodynia in the rat. Pain 93:69–76

    Article  CAS  PubMed  Google Scholar 

  35. Oken MM, Creech RH, Tormey DCet al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    CAS  PubMed  Google Scholar 

  36. Parnis FX, Coleman RE, Harper PG et al (1995) A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer. Eur J Cancer 31A:1721

    Article  CAS  PubMed  Google Scholar 

  37. Peltier AC, Russell JW (2002) Recent advances in drug-induced neuropathies. Curr Opin Neurol 15:633–638

    Article  PubMed  Google Scholar 

  38. Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509–513

    Article  CAS  PubMed  Google Scholar 

  39. Postma TJ, Heimans JJ, Muller MJ et al (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739–744

    Article  CAS  PubMed  Google Scholar 

  40. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol, 249, 9–17

    Google Scholar 

  41. Raymond, E,Faivre, S,Woynarowski, JM,Chaney, SG (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25:4–12

    CAS  Google Scholar 

  42. Rowinsky EK, Eisenhauer EA, Chaudhry V et al (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15

    CAS  Google Scholar 

  43. Russell JW, Windebank AJ, McNiven MA et al (1995) Effect of cisplatin and ACTH4–9 on neural transport in cisplatin induced neurotoxicity. Brain Res 676:258–267

    Article  CAS  PubMed  Google Scholar 

  44. Santini V (2001) Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother 2:479–489

    CAS  PubMed  Google Scholar 

  45. Savarese D, Boucher J, Corey B (1998) Glutamine treatment of paclitaxel-induced myalgias and arthralgias. J Clin Oncol 16:3918–3919

    CAS  Google Scholar 

  46. Schiller JH, Storer B, Tutsch K et al (1994) Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241–248

    CAS  PubMed  Google Scholar 

  47. Schuchter LM, Hensley ML, Meropol NJ, Winer EP (2002) 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20:2895–2903

    Article  PubMed  Google Scholar 

  48. Smith RJ, Wilmore DW (1990) Glutamine nutrition and requirements. JPEN J Parenter Enteral Nutr 14:94S–99S

    CAS  PubMed  Google Scholar 

  49. Strumberg D, Brugge S, Korn MW et al (2002) Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 13:229–236

    Article  CAS  PubMed  Google Scholar 

  50. Tasmuth T, Hartel B, Kalso E (2002) Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 6:17–24

    Article  CAS  PubMed  Google Scholar 

  51. Vahdat L, Papadopoulos K, Lange D et al (2001) Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7:1192–1197

    CAS  PubMed  Google Scholar 

  52. van der Hoop RG, Vecht CJ, van der Burg ME et al (1990) Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer. N Engl J Med 322:89–94

    PubMed  Google Scholar 

  53. van Gerven JM, Hovestadt A, Moll JW et al (1994) The effects of an ACTH (4–9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol 241:432–435

    PubMed  Google Scholar 

  54. Wilson RH, Lehky T, Thomas RR (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767–1774

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Medical Oncology, Weill Medical College of Cornell University, New York, NY, USA

    Allyson J. Ocean & Linda T. Vahdat

  2. 8th Floor, 425 East 61st, New York, NY 10021, USA

    Linda T. Vahdat

Authors
  1. Allyson J. Ocean
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linda T. Vahdat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Linda T. Vahdat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ocean, A.J., Vahdat, L.T. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12, 619–625 (2004). https://doi.org/10.1007/s00520-004-0657-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-004-0657-7

Keywords

Search

Navigation